MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on February 17, 2022, at 1:00 PM (ET). Interested parties can access the webcast through the Company’s website. MannKind is known for developing inhaled therapeutic products, including Afrezza®, an FDA-approved inhaled insulin that is available in the U.S. and Brazil. The webcast will be available for 14 days post-event.
- None.
- None.
DANBURY, Conn., Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 pm (ET).
Interested parties can access a link to the webcast from the New & Events section of the Company’s website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.
Company Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When will MannKind's CEO participate in the SVB Leerink 2022 Global Healthcare Conference?
How can I access the MannKind conference webcast?
What is the focus of MannKind Corporation?
What product is MannKind currently commercializing?
Where is Afrezza available for prescription?
